Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in Women With Diminished Ovarian Reserve
ChiCTR2300069828Phase 4Not yet recruiting
- Sponsor
- Shanxi Medical University
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sirolimus in Diminished Ovarian Reserve (DOR) (2 arms), sponsored by Shanxi Medical University. Primary endpoints: Anti-mullerian hormone, Basal follicle number and 2 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on ChiCTR2300069828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069828.